» Articles » PMID: 31004319

LRP1 Has a Predominant Role in Production over Clearance of Aβ in a Mouse Model of Alzheimer's Disease

Overview
Journal Mol Neurobiol
Date 2019 Apr 21
PMID 31004319
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The low-density lipoprotein receptor-related protein-1 (LRP1) has a dual role in the metabolism of the amyloid precursor protein (APP). In cellular models, LRP1 enhances amyloid-β (Aβ) generation via APP internalization and thus its amyloidogenic processing. However, conditional knock-out studies in mice define LRP1 as an important mediator for the clearance of extracellular Aβ from brain via cellular degradation or transcytosis across the blood-brain barrier (BBB). In order to analyze the net effect of LRP1 on production and clearance of Aβ in vivo, we crossed mice with impaired LRP1 function with a mouse model of Alzheimer's disease (AD). Analysis of Aβ metabolism showed that, despite reduced Aβ clearance due to LRP1 inactivation in vivo, less Aβ was found in cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Further analysis of APP metabolism revealed that impairment of LRP1 in vivo shifted APP processing from the Aβ-generating amyloidogenic cleavage by beta-secretase to the non-amyloidogenic processing by alpha-secretase as shown by a decrease in extracellular Aβ and an increase of soluble APP-α (sAPP-α). This shift in APP processing resulted in overall lower Aβ levels and a reduction in plaque burden. Here, we present for the first time clear in vivo evidence that global impairment of LRP1's endocytosis function favors non-amyloidogenic processing of APP due to its reduced internalization and subsequently, reduced amyloidogenic processing. By inactivation of LRP1, the inhibitory effect on Aβ generation overrules the simultaneous impaired Aβ clearance, resulting in less extracellular Aβ and reduced plaque deposition in a mouse model of AD.

Citing Articles

Xixin Decoction's novel mechanism for alleviating Alzheimer's disease cognitive dysfunction by modulating amyloid-β transport across the blood-brain barrier to reduce neuroinflammation.

Yang C, Zhao E, Zhang H, Duan L, Han X, Ding H Front Pharmacol. 2025; 15():1508726.

PMID: 39834810 PMC: 11743276. DOI: 10.3389/fphar.2024.1508726.


Resilience mechanisms underlying Alzheimer's disease.

Chew C, Lee J, Ng K, Koh R, Chye S Metab Brain Dis. 2025; 40(1):86.

PMID: 39760900 DOI: 10.1007/s11011-024-01507-4.


Exosomes and non-coding RNAs: bridging the gap in Alzheimer's pathogenesis and therapeutics.

Chunhui G, Yanqiu Y, Jibing C, Ning L, Fujun L Metab Brain Dis. 2025; 40(1):84.

PMID: 39754674 PMC: 11700052. DOI: 10.1007/s11011-024-01520-7.


Differential Expression of Neurodegeneration-Related Genes in SH-SY5Y Neuroblastoma Cells Under the Influence of Cyclophilin A: Could the Enzyme be a Likely Trigger and Therapeutic Target for Alzheimer's Disease?.

Pashaei S, Shabani S, Mohammadi S, Morozova-Roche L, Salari N, Rahimi Z Neurochem Res. 2024; 50(1):47.

PMID: 39636462 DOI: 10.1007/s11064-024-04253-2.


Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer's Disease.

Tsoy A, Umbayev B, Kassenova A, Kaupbayeva B, Askarova S Int J Mol Sci. 2024; 25(20).

PMID: 39456746 PMC: 11507512. DOI: 10.3390/ijms252010964.


References
1.
Ulery P, Beers J, Mikhailenko I, Tanzi R, Rebeck G, Hyman B . Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000; 275(10):7410-5. DOI: 10.1074/jbc.275.10.7410. View

2.
Li Y, Marzolo M, van Kerkhof P, Strous G, Bu G . The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J Biol Chem. 2000; 275(22):17187-94. DOI: 10.1074/jbc.M000490200. View

3.
Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuiperi C, Laenen I . Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci. 2000; 20(17):6452-8. PMC: 6772965. View

4.
Ulery P, Strickland D . LRP in Alzheimer's disease: friend or foe?. J Clin Invest. 2000; 106(9):1077-9. PMC: 301424. DOI: 10.1172/JCI11455. View

5.
Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B . Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000; 106(12):1489-99. PMC: 387254. DOI: 10.1172/JCI10498. View